Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

  • Julien Taieb
  • Fernando Rivera
  • Salvatore Siena
  • Meinolf Karthaus
  • Manuel Valladares-Ayerbes
  • Javier Gallego
  • Michael Geissler
  • Reija Koukakis
  • Gaston Demonty
  • Marc Peeters
Author Correction
  • 49 Downloads

Author correction to: J Cancer Res Clin Oncol 144(2):321–335  https://doi.org/10.1007/s00432-017-2534-z

The authors would like to include the following changes in the published article.

In the section Results, under the subsection Depth of response, PEAK, the final sentence should read as follows ‘Median DoR was longer and the resection rate higher in patients with the greatest DpR; the number of responders was also highest in the second top DpR category (Table 3b).’

Table 3: The Group 3 range in the second half (PEAK) of this table should read ‘31–53%’.

Table 3

Efficacy outcomes by depth of response category (a, PRIME; b, PEAK studies) (RAS wild-type population)

a

DpR continuous

(n = 460)

Group 1

<0%

(n = 43)

Group 2

0–30%

(n = 83)

Group 3

31–52%

(n = 116)

Group 4

53–70%

(n = 104)

Group 5

71–100%

(n = 114)

DpR category

 PFS events, n (%)

43 (100.0)

79 (95.2)

107 (92.2)

96 (92.3)

87 (76.3)

 Median PFS (95% CI), months

2.1 (1.9, 3.3)

5.4 (3.9, 6.1)

9.3 (7.6, 10.6)

11.3 (9.7, 13.7)

16.8 (14.6, 21.6)

 HR (95% CI)a

0.78 (0.76, 0.81)

9.86 (6.7, 14.6)

1.70 (1.3, 2.3)

0.79 (0.60, 1.04)

0.46 (0.34, 0.61)

 P value

< 0.0001

< 0.0001

0.0004

0.0915

< 0.0001

 OS events, n (%)

42 (97.7)

79 (95.2)

103 (88.8)

90 (86.5)

66 (57.9)

 Median OS (95% CI), months

7.5 (5.5, 9.4)

12.9 (9.2, 16.1)

18.9 (15.7, 21.4)

30.0 (23.8, 32.5)

48.1 (42.5, 56.0)

 HR (95% CI)a

0.83 (0.81, 0.85)

2.92 (2.03, 4.19)

1.48 (1.10, 1.98)

0.63 (0.48, 0.84)

2.60 (0.19, 0.36)

 P value

< 0.0001

< 0.0001

0.0092

0.0015

< 0.0001

 Responders, n (%)

72 (62.1)

96 (92.3)

97 (85.1)

 Median DoR (95% CI), months

7.6 (5.5, 9.5)

9.4 (7.9, 10.1)

13.9 (11.1, 19.3)

 Any resection, n (%)

0 (0.0)

0 (0.0)

6 (5.2)

6 (5.8)

51 (44.7)

 R0 resection, n (%)

0 (0.0)

0 (0.0)

5 (4.3)

1 (1.0)

39 (34.2)

b

DpR continuous

(n = 158)

Group 1

<0%

(n = 3)

Group 2

0–30%

(n = 33)

Group 3

31–53%

(n = 41)

Group 4

54–82%

(n = 40)

Group 5

83–100%

(n = 41)

DpR category

 PFS events, n (%)

3 (100.0)

30 (90.9)

39 (95.1)

39 (97.5)

28 (68.3)

 Median PFS (95% CI), months

3.9 (1.8, 3.9)

7.6 (5.7, 11.6)

9.5 (7.2, 12.6)

13.0 (10.7, 15.1)

18.8 (13.2, 24.8)

 HR (95% CI)a

0.80 (0.75, 0.85)

18.98 (5.0, 72.4)

1.54 (1.0, 2.5)

0.69 (0.44, 1.08)

0.27 (0.16, 0.45)

 P value

< 0.0001

<0.0001

0.0781

0.1007

<0.0001

 OS events, n (%)

2 (66.7)

29 (87.9)

37 (90.2)

29 (72.5)

9 (22.0)

 Median OS (95% CI), months

15.0 (8.9, 21.2)

17.3 (11.1, 21.8)

23.9 (16.9, 28.9)

36.5 (26.0, 43.8)

63.0 (48.0, NE)

 HR (95% CI)a

0.78 (0.73, 0.83)

2.62 (0.62, 11.05)

1.26 (0.77, 2.05)

0.49 (0.30, 0.80)

0.09 (0.04, 0.19)

 P value

< 0.0001

0.1898

0.3543

0.0046

< 0.0001

 Responders, n (%)

34 (82.9)

38 (95.0)

33 (80.5)

 Median DoR (95% CI), months

7.9 (5.5, 9.2)

11.1 (8.4, 13.5)

17.0 (10.3, 23.2)

 Any resection, n (%)

0 (0.0)

1 (3.0)

0 (0.0)

2 (5.0)

20 (48.8)

 R0 resection, n (%)

0 (0.0)

1 (3.0)

0 (0.0)

0 (0.0)

15 (36.6)

CI confidence interval, DpR depth of response, HR hazard ratio, NE not evaluable, OS overall survival, PFS progression-free survival, R0 complete resection

aGroup HR compared with Group 3, continuous HR estimate is for the HR associated with a 10% difference in DpR

bTest for trend

Figure 6b: The DpR ranges for Groups 3, 4 and 5 in the key should read: ‘Group 3 (DpR 31–53%); Group 4 (DpR 54–82%); Group 5 (DpR 83–100%)’.

Fig. 6

Impact of depth of response (DpR) on survival in the PEAK study (a progression-free survival; b overall survival) (RAS wild-type population) censor indicated by vertical bar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Julien Taieb
    • 1
  • Fernando Rivera
    • 2
  • Salvatore Siena
    • 3
  • Meinolf Karthaus
    • 4
  • Manuel Valladares-Ayerbes
    • 5
  • Javier Gallego
    • 6
  • Michael Geissler
    • 7
  • Reija Koukakis
    • 8
  • Gaston Demonty
    • 9
  • Marc Peeters
    • 10
  1. 1.Department of Hepatogastroenterology and GI OncologyGeorges Pompidou European Hospital and Sorbonne Paris Cité / Université Paris DescartesParisFrance
  2. 2.Hospital Universitario Marqués de ValdecillaSantanderSpain
  3. 3.Niguarda Cancer CenterGrande Ospedale Metropolitano Niguarda and Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di MilanoMilanItaly
  4. 4.Städtisches Klinikum MünchenMunichGermany
  5. 5.Virgen del Rocio HospitalSevilleSpain
  6. 6.Hospital General Universitario de ElcheElcheSpain
  7. 7.Klinikum EsslingenEsslingenGermany
  8. 8.BiostatisticsAmgen LtdUxbridgeUK
  9. 9.Medical DevelopmentAmgen (Europe) GmbHZugSwitzerland
  10. 10.Antwerp University HospitalAntwerpBelgium

Personalised recommendations